Approval By The U.S. Fda For Clinical Trial Of The Mrna Herpes Zoster Vaccine Its Humoral And Cellular Immunity Was Significantly Higher Than Those Of Internationally Commercially Available Recombinant Subunit Vaccines

2025-03-24 Source:Aimbio
The clinical trial approval for the mRNA herpes zoster vaccine has been recently received from the U.S. Food and Drug Administration (“FDA”). This is the second innovative vaccine product of the Group approved by the U.S. FDA for clinical trials, following the mRNA RSV vaccine, which marks a new milestone in the Group’s globalization strategy.

In preclinical testing, results from a third-party testing unit showed that the Group’s mRNA herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of international commercially available recombinant subunit control vaccines.

Previous:It's already the first one Next:Significant Decrease In Loss Of The Company’S Results